following a full submission:
delta-9-tetrahydrocannabinol and cannabidiol (Sativex®) is accepted for use within NHSScotland.
Indication under review: As treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
In four phase III/IV studies, Sativex® was associated with greater improvements in patient reported spasticity symptom numerical rating score (NRS) and response rate compared with placebo.
Medicine details
- Medicine name:
- delta-9-tetrahydrocannabinol and cannabidiol (Sativex)
- SMC ID:
- SMC2473
- Indication:
Indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
- Pharmaceutical company
- GW Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 September 2022